These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 7826496)

  • 1. Early detection of neuroleptic-induced parkinsonism in elderly patients with dementia.
    Sweet RA; Pollock BG; Rosen J; Mulsant BH; Altieri LP; Perel JM
    J Geriatr Psychiatry Neurol; 1994; 7(4):251-3. PubMed ID: 7826496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence and predictors of drug-induced parkinsonism in older psychiatric patients treated with very low doses of neuroleptics.
    Caligiuri MP; Lacro JP; Jeste DV
    J Clin Psychopharmacol; 1999 Aug; 19(4):322-8. PubMed ID: 10440459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroleptic-Induced Parkinsonism in Elderly Patients Diagnosed With Psychotic Major Depression and Dementia of the Alzheimer Type.
    Sweet RA; Mulsant BH; Pollock BG; Rosen J; Altieri LP
    Am J Geriatr Psychiatry; 1996 Autumn; 4(4):311-319. PubMed ID: 28530968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term depot neuroleptic treatment with perphenazine decanoate. I. Efficacy and side effects in a 12 month study of 42 drug monitored psychotic patients.
    Knudsen P; Hansen LB; Højholdt K; Larsen NE
    Acta Psychiatr Scand Suppl; 1985; 322():29-40. PubMed ID: 3907279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relationship between blood perphenazine levels, early resolution of psychotic symptoms, and side effects.
    Mazure CM; Nelson JC; Jatlow PI; Kincare P; Bowers MB
    J Clin Psychiatry; 1990 Aug; 51(8):330-4. PubMed ID: 2199431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of plasma homovanillic acid with behavioral symptoms in patients diagnosed with dementia: a preliminary report.
    Sweet RA; Pollock BG; Mulsant BH; Rosen J; Lo KH; Yao JK; Henteleff RA; Mazumdar S
    Biol Psychiatry; 1997 Dec; 42(11):1016-23. PubMed ID: 9386853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Instrumental motor predictors of neuroleptic-induced parkinsonism in newly medicated schizophrenia patients.
    Caligiuri MP; Lohr JB
    J Neuropsychiatry Clin Neurosci; 1997; 9(4):562-7. PubMed ID: 9447497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extrapyramidal side effects in patients with Alzheimer's disease treated with low-dose neuroleptic medication.
    Caligiuri MP; Rockwell E; Jeste DV
    Am J Geriatr Psychiatry; 1998; 6(1):75-82. PubMed ID: 9469217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liverpool University Neuroleptic Side-Effect Rating Scale (LUNSERS) as a subjective measure of drug-induced parkinsonism and akathisia.
    Jung HY; Kim JH; Ahn YM; Kim SC; Hwang SS; Kim YS
    Hum Psychopharmacol; 2005 Jan; 20(1):41-5. PubMed ID: 15565639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroleptic-induced parkinsonism facilitated by alcohol.
    Lutz EG
    J Med Soc N J; 1978 Jun; 75(6):473-4. PubMed ID: 275503
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical characteristics of neuroleptic-induced parkinsonism.
    Hassin-Baer S; Sirota P; Korczyn AD; Treves TA; Epstein B; Shabtai H; Martin T; Litvinjuk Y; Giladi N
    J Neural Transm (Vienna); 2001; 108(11):1299-308. PubMed ID: 11768628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute neuroleptic treatment in elderly patients without dementia.
    Mazure CM; Nelson JC; Jatlow PI; Bowers MB
    Am J Geriatr Psychiatry; 1998; 6(3):221-9. PubMed ID: 9659955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of vitamin E addition to acute neuroleptic treatment on the emergence of extrapyramidal side effects in schizophrenic patients: an open label study.
    Dorfman-Etrog P; Hermesh H; Prilipko L; Weizman A; Munitz H
    Eur Neuropsychopharmacol; 1999 Dec; 9(6):475-7. PubMed ID: 10625114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacologic profile of perphenazine's metabolites.
    Sweet RA; Pollock BG; Mulsant BH; Rosen J; Sorisio D; Kirshner M; Henteleff R; DeMichele MA
    J Clin Psychopharmacol; 2000 Apr; 20(2):181-7. PubMed ID: 10770456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective cytochrome P450 phenotyping for neuroleptic treatment in dementia.
    Pollock BG; Mulsant BH; Sweet RA; Rosen J; Altieri LP; Perel JM
    Psychopharmacol Bull; 1995; 31(2):327-31. PubMed ID: 7491387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Susceptibility to neuroleptic-induced parkinsonism--age and increased substantia nigra echogenicity as putative risk factors.
    Jabs BE; Bartsch AJ; Pfuhlmann B
    Eur Psychiatry; 2003 Jun; 18(4):177-81. PubMed ID: 12814851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of extrapyramidal symptoms during acute neuroleptic treatment.
    Mazure CM; Cellar JS; Bowers MB; Nelson JC; Takeshita J; Zigun B
    J Clin Psychiatry; 1995 Mar; 56(3):94-100. PubMed ID: 7883736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term depot neuroleptic treatment with perphenazine decanoate. II. Different depot intervals in the last 6 months of a 12 month study of 42 drug monitored psychotic patients.
    Knudsen P; Hansen LB; Højholdt K; Larsen NE
    Acta Psychiatr Scand Suppl; 1985; 322():41-50. PubMed ID: 3934921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perphenazine decanoate vs. perphenazine enanthate: efficacy and side effects in a 6 week double-blind, comparative study of 50 drug monitored psychotic patients.
    Knudsen P; Hansen LB; Auken G; Waehrens J; Højholdt K; Larsen NE
    Acta Psychiatr Scand Suppl; 1985; 322():15-28. PubMed ID: 3907278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Viewpoint: challenges in our understanding of neuroleptic induced parkinsonism.
    Friedman JH
    Parkinsonism Relat Disord; 2014 Dec; 20(12):1325-8. PubMed ID: 25456826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.